SEHK:158
SEHK:158Real Estate

Melbourne Enterprises (SEHK:158) EPS Loss Deepens, Reinforcing Bearish Profitability Narrative

Melbourne Enterprises FY 2025 Earnings Snapshot Melbourne Enterprises (SEHK:158) has just posted its FY 2025 first half numbers, with revenue of HK$81.9 million and EPS of -HK$5.66, setting the tone for what remains a loss-making period. Looking back over recent halves, the company has seen revenue move from HK$79.9 million in 1H FY 2024 to HK$81.8 million in 2H FY 2024 and HK$81.9 million in 1H FY 2025. Over the same stretch, EPS has swung from HK$0.76 to -HK$7.01 and now -HK$5.66. This...
SEHK:992
SEHK:992Tech

The Bull Case For Lenovo Group (SEHK:992) Could Change Following AI-Focused ThinkSystem And ThinkAgile Launch – Learn Why

In December 2025, Lenovo announced a broad lineup of new ThinkSystem and ThinkAgile data storage, virtualization solutions, and AI-ready data management services aimed at modernizing enterprise and mid-market IT infrastructure. A distinctive element of this launch is Lenovo's push into open, hyperconverged and lifecycle services, such as TruScale-based storage and hybrid cloud advisory, designed to help customers unlock more value from AI workloads. Next, we’ll explore how Lenovo’s push into...
SEHK:1672
SEHK:1672Biotechs

Do Ascletis Pharma’s (SEHK:1672) ASC50 Phase I Results Hint At A Scalable Autoimmune Strategy?

Ascletis Pharma recently reported positive topline results from a U.S. Phase I trial of ASC50, an in-house oral IL‑17 inhibitor for mild to moderate psoriasis, showing favorable safety, tolerability and target engagement across multiple dose levels with no serious adverse events. The data support convenient once-daily or potentially once-weekly oral dosing and extend patent protection on this new chemical entity through 2043, underscoring a differentiated approach within the autoimmune and...